Wall Street Zen Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to Sell

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research analysts also recently commented on TVRD. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Barclays set a $5.00 price target on Tvardi Therapeutics and gave the stock an “equal weight” rating in a research report on Monday, October 13th. Cantor Fitzgerald lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. BTIG Research cut their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, October 13th. Finally, Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Price Performance

Shares of TVRD opened at $6.58 on Friday. Tvardi Therapeutics has a fifty-two week low of $5.65 and a fifty-two week high of $43.65. The business has a 50 day simple moving average of $30.22.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics in the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics in the second quarter worth $80,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics in the second quarter worth $92,000. Finally, Bank of America Corp DE purchased a new position in Tvardi Therapeutics during the second quarter valued at $399,000. 44.66% of the stock is owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.